LMR Partners LLP Takes $264,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

LMR Partners LLP bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 15,150 shares of the company’s stock, valued at approximately $264,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Spire Wealth Management acquired a new position in Bicara Therapeutics during the 4th quarter worth about $31,000. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics during the 4th quarter worth about $32,000. Legal & General Group Plc acquired a new position in Bicara Therapeutics during the 4th quarter worth about $33,000. Summit Investment Advisors Inc. acquired a new position in Bicara Therapeutics during the 4th quarter worth about $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics during the 4th quarter worth about $69,000.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $13.70 on Thursday. The business has a 50-day moving average price of $12.82 and a two-hundred day moving average price of $15.43. Bicara Therapeutics Inc. has a 1-year low of $8.91 and a 1-year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). On average, equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on BCAX shares. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, April 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Wedbush reissued an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Finally, Wells Fargo & Company initiated coverage on Bicara Therapeutics in a report on Thursday, April 17th. They set an “underweight” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.43.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.